Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

“…Development of the prognostic model Construction of the six-factor prognostic model has been previously described. 4,11 In brief, the following steps were involved: i) key clinico-pathological factors were identified and dichotomised for high/low values as necessary; ii) association between baseline clinicopathological factors and OS was investigated using a univariate Cox proportional hazards model; iii) factors that were significant on univariate analysis were incorporated into a multivariate Cox proportional hazards regression model (step-wise procedure); iv) factors that were significant on multivariate analysis were incorporated into the final model, which was then subjected to validation by a bootstrapping approach; v) the C-index was used to determine accuracy of the model, which comprised six separate RFs; and vi) patients were then classified into risk groups based on the number of baseline RFs with median OS calculated for each risk group.…”

Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis

“…At this stage, palliation is the main target of any treatment. Many palliative therapies, including systemic chemotherapy (e.g., docetaxel and cabazitaxel) and recently developed antiandrogenic therapies (e.g., abiraterone and enzalutamide), are available (43,44). A consensus about the optimal timing and type of treatments has not been reached yet.…”

“…In recent years, patients who developed CRPC were offered a new generation of ADT (such as abiraterone and enzalutamide), with good results in terms of biochemical response and pharmacologic effects (43,44). De Giorgi et al (19,46) assessed the usefulness of 18 F-choline PET/CT for evaluating the early response to treatment with abiraterone and enzalutamide in mCRPC patients.…”

Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem

“…Также в группе больных с более длительной продолжительностью первичной кастрационной ГТ достоверно чаще регистрировали снижение уровня ПСА  50 % (41 и 16 %, р = 0,005). В недавно опубликованных данных мультицентро-вого клинического исследования канадских авторов, включавшего 519 больных, которые получали абира-терон в 1-й линии и после доцетаксела, также пока-зано, что длительность АДТ до развития кастрацион-ной резистентности (больше или меньше 36 мес) является независимым фактором прогноза ОВ в мно-гофакторном анализе [28]. Таким образом, при выбо-ре варианта терапии 1-й линии КРРПЖ следует при-нимать во внимание, что у больных с относительно непродолжительным ответом на АДТ (< 18-24 мес) вряд ли можно рассчитывать на длительный ответ при назначении АДТ, и назначение доцетаксела у этих больных более оправдано.…”

“…В указан-ных выше мультицентровых исследованиях, проведен-ных во Франции и Канаде, длительность АДТ до раз-вития рефрактерности была наиболее значимым фактором прогноза ответа на терапию абиратероном после доцетаксела [27,28]. В исследовании M. Afshar и соавт.…”